Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. - Wikidata - awgldk - TriplyDB

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

http://www.wikidata.org/entity/Q36905632

about

Wnt/beta-catenin signaling and small molecule inhibitors Wnt signaling pathway in non-small cell lung cancer Narrowing the focus: a toolkit to systematically connect oncogenic signaling pathways with cancer phenotypes Synthetic lethality in lung cancer and translation to clinical therapies TNKS1BP1 functions in DNA double-strand break repair though facilitating DNA-PKcs autophosphorylation dependent on PARP-1 Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer Differential transcriptional effects of EGFR inhibitors Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer FH535 Suppresses Osteosarcoma Growth In Vitro and Inhibits Wnt Signaling through Tankyrases Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.β-catenin contributes to lung tumor development induced by EGFR mutations Using functional genomics to overcome therapeutic resistance in hematological malignancies.Evidence for tankyrases as antineoplastic targets in lung cancer.Tissue-specific stem cells in the myometrium and tumor-initiating cells in leiomyoma.Computational discovery of pathway-level genetic vulnerabilities in non-small-cell lung cancer.Using activation status of signaling pathways as mechanism-based biomarkers to predict drug sensitivity Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling.Targeting developmental pathways in children with cancer: what price success?The Poly(ADP-ribose) Polymerase Enzyme Tankyrase Antagonizes Activity of the β-Catenin Destruction Complex through ADP-ribosylation of Axin and APC2 Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth Tankyrases as drug targets.Tankyrases: structure, function and therapeutic implications in cancer.Intracellular signals of lung cancer cells as possible therapeutic targets.Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review.Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors.Wnt signaling as potential therapeutic target in lung cancer.Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.Tankyrase Inhibitor Sensitizes Lung Cancer Cells to Endothelial Growth Factor Receptor (EGFR) Inhibition via Stabilizing Angiomotins and Inhibiting YAP Signaling.Tankyrase-mediated β-catenin activity regulates vasopressin-induced AQP2 expression in kidney collecting duct mpkCCDc14 cells.Notch4 promotes gastric cancer growth through activation of Wnt1/β-catenin signaling.Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer Targeting Tankyrase to Fight WNT-dependent Tumours.Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer.AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.Molecular genetics and targeted therapy of WNT-related human diseases (Review).Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.

P2860

Q24597197-9963986E-7828-4D90-9FB0-B8494A28E322 Q26825936-3B2D39A3-C043-42D2-AB80-1EACF4EBAEDE Q28072745-F6F5E567-BB4D-4282-853C-91741568CB9E Q28072904-F97F39D0-99B7-40D3-801E-F709BBDC27DE Q28115068-40E4C877-7459-451D-B412-1D5F3079437D Q28534819-18C507DB-650D-412E-AB4B-3D9C9A6584D6 Q28542713-90CAF3E2-071B-40AB-9E81-9BFCD21E3F87 Q28547446-81C44204-D783-476E-9A5A-63B9097D845B Q33715651-848022F4-242B-446C-9720-4508FDE7BCDD Q34103108-D96DDBFA-82A1-4775-8C11-46C706AA1915 Q34353437-566EAC99-9190-4BC8-92F8-985E14FF8D27 Q34401328-CC66A420-B2D7-46C9-A5A8-E686B101598B Q34690600-773F1320-4406-4CC8-BBAC-492BEBFE6312 Q35617315-42B5658C-910B-4B24-9BF9-64DB2429BC14 Q35891380-F6FC0720-AC4F-4989-9CC1-3730F9E6B5CE Q36382520-707BCE0D-26AC-4DD3-9111-02FA7FD8219F Q36544073-7155BF46-62CE-41AC-88AE-3B852F632E04 Q36562360-237B5991-ED5B-489D-B784-F95C68F7BB72 Q36905620-E3BFF9D5-DCB4-46AD-9C5A-9F35C5FEE06B Q37066468-FAC1B4FE-C8A8-4DDD-85DA-A10474DDE675 Q37240573-8D0F7C76-D8C8-4CC5-B314-95469E179851 Q38104494-77451934-D734-4D13-BACB-9A245E12DFB2 Q38224266-ED15699B-171A-46E7-9F97-D9C94CE9DC92 Q38364439-45988C54-6CA9-4849-8D71-06071A1FFF8C Q38390205-758A3E99-6D7F-482A-89B3-74FDDBFBA498 Q38733091-41EF7EE9-5A9D-4FA5-AF42-5D5E3B74BD26 Q38735754-9B9EB22E-A926-4506-A415-DC8AE05ABD19 Q38745430-74CC5A7C-F365-46AF-9C3C-92C1D621C10E Q38768184-F508DEA1-C824-4BE0-8439-2A987B2DFF7E Q38927549-0D75B8F2-B6C0-4D2E-896E-F83E5596C405 Q38928324-95D50D13-955D-4478-83FE-3E32313AB255 Q39140763-7F77758F-4B10-46E2-8CAB-AADB582EF68F Q39216658-F5505E4D-679E-44B4-AE06-5EDA518B69AE Q39288360-56959CC3-E3E7-43FC-871E-0A89C1332351 Q39356323-781C8EF9-DEDB-49FD-A067-1E7EE6E367C9 Q39450241-3DDE3101-250D-46BA-8DF8-C9340A57FC4D Q41561392-455DF680-AA52-4349-868C-CB04F9F768BF Q41942200-863FD561-073F-4A33-AE7B-865EBA3ACB19 Q42820746-B9AA89FD-ABF8-4D32-99A5-4BD2D724FCE6 Q47131999-7EF4EA69-9E2C-41D9-AF34-4F7C5AE00B39

P2860

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

http://www.wikidata.org/entity/Q36905632

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

@en

type

label

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

@en

prefLabel

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

@en

P1433

Q36905632-41BF3DA8-C9BD-4667-A06F-9755812D961E

P1476

Q36905632-30F3590A-0A04-4088-A1B9-86954092163D

P2093

Q36905632-1441DDEC-B71C-4956-87E1-B2DDDCCA55A0

Q36905632-1C84E12B-BFF2-413C-B986-9D8EE772B3B1

Q36905632-36C7E1B8-7A18-4E9B-9687-536C22755C28

Q36905632-4CEA6F97-8484-4057-88AD-BF274386A43C

Q36905632-602DA969-37D5-428C-8BA7-889DD1513A4D

Q36905632-65EE60A0-7532-4BF7-9EF9-7EE11F2A62A6

Q36905632-85DD710F-6178-4175-9E57-78F2E03185B6

Q36905632-B6048BE0-DA73-4787-AE32-93E840DC86D6

Q36905632-C4E2AE0D-9AD8-4671-A4D0-20FD4E77E0DE

Q36905632-DE15E53E-6C2A-4E99-BD1F-D3484D4E9063

P2860

Q36905632-0228438B-7D27-46F7-A819-E6DC74B2EB79

Q36905632-075A2E56-EEC3-4803-B5AC-73E117689418

Q36905632-07A22433-8F60-442A-B704-E552316DEBEE

Q36905632-114B70F1-F1B4-4AA4-86ED-4F1ED952CF86

Q36905632-1D10CA69-4333-49DF-85A6-BB700AE31AD6

Q36905632-1FF987A6-052B-4727-A365-2D69A0A7942A

Q36905632-20359C12-68C0-48A9-9DF1-18D237F012E8

Q36905632-21EF398E-B4EC-4E02-B18A-B84D023F1431

Q36905632-25019AF2-7B0C-4732-A69C-DBEC43B15EA6

Q36905632-2E4D4C27-A6C1-43CB-9DE6-A947B65867BD

P304

Q36905632-F9237668-6838-49E4-A137-4243CD21F57B

P31

Q36905632-0D41466C-01BD-4EFA-A9BE-39051302BA7E

P356

Q36905632-90F099CB-1252-43E0-9AA9-A858057CEAD8

P407

Q36905632-45502221-756C-417D-80ED-F70BA19344F9

P433

Q36905632-B05459E1-AFA1-4ED6-A579-DA7EA3164338

P478

Q36905632-320139CA-FDE3-4FF5-BA24-3D9FE16DA226

P577

Q36905632-9ACBA1BE-2378-4013-A491-BCE67F065941

P698

Q36905632-FA22F423-14B2-4634-A380-18C5C331BF46

P932

Q36905632-C5D0A77F-970E-4659-BB24-65DAFD01FFCD

P356

0008-5472.CAN-11-2848

P1433

Cancer Research

P1476

Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.

@en

P2093

Aik Choon Tan

http://www.w3.org/2001/XMLSchema#string

Barbara A Helfrich

http://www.w3.org/2001/XMLSchema#string

Christopher C Porter

http://www.w3.org/2001/XMLSchema#string

Daniel C Chan

http://www.w3.org/2001/XMLSchema#string

Dexiang Gao

http://www.w3.org/2001/XMLSchema#string

Hannah A Scarborough

http://www.w3.org/2001/XMLSchema#string

James DeGregori

http://www.w3.org/2001/XMLSchema#string

Jihye Kim

http://www.w3.org/2001/XMLSchema#string

Matias Casás-Selves

http://www.w3.org/2001/XMLSchema#string

Paul A Bunn

http://www.w3.org/2001/XMLSchema#string

P2860

Ultrafast and memory-efficient alignment of short DNA sequences to the human genome

Global cancer statistics

CK2 phosphorylation of the armadillo repeat region of beta-catenin potentiates Wnt signaling

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma

Casein kinase I phosphorylates and destabilizes the beta-catenin degradation complex

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells

New molecularly targeted therapies for lung cancer

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

P304

4154-4164

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-11-2848

http://www.w3.org/2001/XMLSchema#string

P407

P433

16

http://www.w3.org/2001/XMLSchema#string

P478

72

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22738915

http://www.w3.org/2001/XMLSchema#string

P932

3673784

http://www.w3.org/2001/XMLSchema#string